ANKMY2

Across TCGA pan-cancer cohorts, ANKMY2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ANKMY2 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ANKMY2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ANKMY2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and GBM show a favorable association.

CCRCC, PDAC, and UCEC are the cancer types where ANKMY2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	All	0.773	0.963	.013	15	view →
PDAC	OS	Quartile	III,IV	0.163	0.758	.006	11	view →
UCEC	OS	Median	III,IV	0.341	0.902	.032	10	view →
HNSC	OS	Tertile	III,IV	0.821	0.536	.013	9	view →
GBM	OS	Quartile	All	0.670	0.387	.031	3	view →
LUAD	OS	Tertile	II,III,IV	0.839	0.300	.026	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ANKMY2–CCRCC (OS)

Open the CCRCC breakdown →